CRISPR Market by Offering (Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)), Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030

icon1
USD 5.47 BN
MARKET SIZE, 2030
icon2
CAGR 11.2%
(2025-2030)
icon3
270
REPORT PAGES
icon4
301
MARKET TABLES

OVERVIEW

crispr-technology-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The CRISPR market is projected to reach USD 5.47 billion in 2030 from USD 3.21 billion in 2025, at a CAGR of 11.2%. The major factors driving the growth of the CRISPR market are the growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology. Development of new vaccines and treatments for genetic diseases along with expanding industrial and agricultural applications of CRISPR are set to open new avenues of market expansion.

KEY TAKEAWAYS

  • By Region
    The North America CRISPR market accounted for a 49.8% revenue share in 2024.
  • By Offering
    By offering, the CRISPR products segment is expected to dominate the market throughout the forecast period.
  • By Application
    By application, the drug discovery & development segment is projected to grow at the fastest rate from 2025 to 2030.
  • By End User
    By end user, the pharma & biotech segment is expected to dominate the market throughout the forecast period.
  • Key Players
    Companies like Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US) were identified as some of the star players in the CRISPR market (global), given their strong market share and product footprint.
  • SMEs
    Companies like Creative Biogene (US), Hera BioLabs (US), Fujian SunyBiotech Co., Ltd. (China), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

Gene therapies utilizing CRISPR technology offer the potential to address unmet medical needs by targeting the underlying genetic causes of diseases. Patients are opting for novel treatments that can provide potential cures or significant improvements in their conditions. Some of the major recent advancements in CRISPR technology are base editors and Cas9 variants. Base editors are a new type of CRISPR-Cas9 tool that can directly change individual nucleotides in DNA without the need for double-stranded breaks. The development of new vaccines and treatments for genetic diseases using CRISPR technology presents a transformative opportunity in the field of healthcare.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on customers’ business in the CRISPR market is being driven by the need for faster, safer, and more precise editing across research and translational programs. Core buyers—pharma/biotech, academic & core labs, CROs/CDMOs, and emerging diagnostics & agribio players are shifting spend from plasmid Cas9 and KO-only kits toward RNP-based workflows, high-fidelity nucleases, and next-gen libraries (CRISPRi/a, base/prime editing, single-cell/Perturb-seq–ready). Imperatives include raising on-target efficiency and specificity, solving delivery for hard-to-edit systems (iPSC, HSC, T/NK) with AAV/LNP/non-viral kits, and standardizing IND-grade QC (NGS off-target, long-read confirmation) with clear FTO/GMP supply. As users integrate design software + barcoded libraries + analytics into end-to-end bundles, vendors that package kits, enzymes, and informatics win share. For clients’ clients—patients, payers, and regulators—the result is more precise therapies, faster path to clinic, and lower late-stage attrition; in diagnostics and AgBio, it translates to quicker, sensitive assays and higher-performance traits. Overall, demand is migrating from commodity reagents to platformized CRISPR workflows that deliver edit success, regulatory-ready data, and scalability..

crispr-technology-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing demand for CRISPR-based gene therapies.
  • Advancements in CRISPR technology.
RESTRAINTS
Impact
Level
  • Technical challenges associated with CRISPR technology.
OPPORTUNITIES
Impact
Level
  • Development of new vaccines and treatments for genetic diseases.
  • Expanding industrial and agricultural applications of CRISPR.
CHALLENGES
Impact
Level
  • Regulatory hurdles for CRISPR advancements.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing demand for CRISPR-based gene therapies.

Gene therapies utilizing CRISPR technology offer the potential to address unmet medical needs by targeting the underlying genetic causes of diseases. Patients are opting for novel treatments that can provide potential cures or significant improvements in their conditions. Clinical trials have shown promising results in various disease areas, including blood disorders, inherited retinal diseases, and certain types of cancer. A landmark study published in the New England Journal of Medicine in 2023 reported results from pivotal trials of exagamglogene autotemcel (exa-cel), a CRISPR–Cas9–based therapy for transfusion-dependent β-thalassemia (TDT) and sickle-cell disease (SCD).

Restraint: Technical challenges associated with CRISPR technology.

Technical challenges associated with CRISPR technology present a significant restraint in the field of gene editing. While CRISPR holds immense potential, certain obstacles hinder its widespread implementation. These challenges arise from the complexities involved in precise genome editing, off-target effects, and delivery efficiency. Addressing these technical hurdles is crucial for harnessing the full potential of CRISPR technology and realizing its transformative impact in various industries.

Opportunity: Development of new vaccines and treatments for genetic diseases.

The development of new vaccines and treatments for genetic diseases using CRISPR technology presents a transformative opportunity in the field of healthcare. CRISPR's precise gene editing capabilities hold immense potential in combating infectious diseases and addressing the underlying genetic causes of various disorders. For instance, Editas Medicine is conducting a phase 1/2 trial for individuals with severe sickle cell disease (SCD) but using a CRISPR system with a Cas12a protein rather than the more established Cas9 protein. Moreover, Vertex Pharmaceuticals and CRISPR Therapeutics are working together on beta-thalassemia. The clinical trial is in its second phase.

Challenge: Regulatory hurdles for CRISPR advancements.

Regulatory hurdles pose significant challenges in the field of CRISPR technology, impacting its widespread adoption and market growth. As a revolutionary gene editing tool, CRISPR holds immense potential but faces regulatory complexities due to ethical concerns, safety considerations, and the need for comprehensive guidelines. Addressing these regulatory challenges is crucial for fostering innovation, ensuring patient safety, and unlocking the full potential of CRISPR technology.

crispr-technology-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Partnership with Mammoth Biosciences to co-develop a hand-held, disposable CRISPR (DETECTR) diagnostic for COVID-19, aiming at over-the-counter use. Demonstrates Cas12-based diagnostics at point-of-need: rapid time-to-result, instrument-light workflow, and scalability for other infectious targets beyond SARS-CoV-2.
Collaboration with Revvity to embed CRISPR gene-editing & screening services into AZ’s discovery platform/Functional Genomics Centre (FGC), supporting target ID/validation across oncology and other areas. Shows pharma outsourcing to CRISPR service platforms: higher-throughput functional genomics, standardized libraries & analytics, and faster target-to-lead decisions with shared infrastructure.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The ecosystem analysis of the CRISPR market provides a comprehensive overview of the interconnected network of stakeholders, resources, and interactions that shape the industry’s dynamics. Central to this ecosystem are various entities involved in the development, manufacturing, distribution, and utilization of CRISPR technologies. This includes technology developers, instrument manufacturers, service providers, and end users, such as research institutions, pharmaceutical companies, and biotechnology firms. Regulatory authorities and standards organizations also play crucial roles, influencing market trends, innovation, and the ethical use of genomic data.

crispr-technology-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

crispr-technology-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

CRISPR Market, By Offering

As of 2024, CRISPR kits & enzymes segment held the largest share of the CRISPR market and will continue leading the market through 2030. Growth in this market segment can be attributed to the increasing demand for CRISPR reagents & consumables in genome editing workflows. The CRISPR kits & enzymes segment includes products and tools utilized in genome editing based on CRISPR-Cas9 technology.

CRISPR Market, By Application

In 2024, drug discovery & development application segment is expected to grow at the fastest pace during the forecast period. Factors such as the rising expenditure for innovative drug development and the growing preference for personalized medicine are expected to support the growth of the drug discovery & development application segment.

CRISPR Market, By End User

The pharma & biotech companies segment is expected to dominate the CRISPR market through the forecast period. Factors such as increasing investments in innovative drug development and the rising demand for personalized medicine are expected to drive the growth of the pharmaceutical and biotechnology sectors.

REGION

Asia Pacific to be the fastest growing region in the CRISPR market during forecast period

The Asia Pacific region is expected to be the fastest-growing market for CRISPR due to the increasing awareness of the importance of CRISPR-based therapies, rising demand for personalized medicine, and advancements in gene editing technologies. Another key driver for the Asia Pacific CRISPR market is the region's large and rapidly aging population. The development of high-throughput CRISPR-based technologies has made it possible to innovate new gene editing techniques.

crispr-technology-market Region

crispr-technology-market: COMPANY EVALUATION MATRIX

In the CRISPR key players market matrix, Thermo Fisher Scientific, Inc. (Star) leads with a strong market share and extensive product & service footprint. The company focuses on delivering products and services related to CRISPR technology to enhance its global presence, the company prioritizes investments in research and development. New England Biolabs (Emerging Leader) is gaining visibility with its specialized solutions and tailored solutions for CRISPR. The company's expanding its regional presence and caters to a comprehensive portfolio of service offerings, it also collaborates with industry partners to support the development of molecular diagnostics and nucleic acid vaccines.

crispr-technology-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 2.90 Billion
Market Forecast in 2030 (Value) USD 5.47 Billion
Growth Rate CAGR of 11.2% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Offering:
    • Products
    • Services
  • By Product Type:
    • CRISPR Kits & Enzymes
    • CRISPR Libraries
    • Other Products
  • By Service Type:
    • gRNA Synthesis & Cell Line Development
    • Screening & Validation
    • Other Services
  • By Application:
    • Discovery & Development
    • Agriculture
    • Other Applications
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
    • Other End Users
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East, and Africa

WHAT IS IN IT FOR YOU: crispr-technology-market REPORT CONTENT GUIDE

crispr-technology-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Competitive Landscape Analysis Additional profiles of regional/local players, their market position/share, strategies, and service portfolios Insights to uncover market gaps and refine differentiation strategies.
End User Market Assessment Comprehensive list of end users typically engaged in discovery, development & manufacturing of biologics (cell therapy, gene therapy) across targeted regions/countries. Insights on identifying potential customers of CRISPR services
Cross-segmental Analysis Cross-segmental analysis between CRISPR products and applications Insights on White Spaces & Unmet Needs, interconnections and supply chain opportunities.

RECENT DEVELOPMENTS

  • July 2024 : Agilent Technologies, Inc. (US) acquired BioVectra, Inc. (Canada), enhancing its biopharma solutions with BioVectra’s expertise in biologics and gene editing. The acquisition expanded Agilent’s capabilities in drug development and manufacturing..
  • May 2024 : Merck KGaA acquired Mirus Bio, Inc. (US), integrating Mirus Bio's transfection technology with Merck's bioprocessing expertise. This acquisition enhanced Merck’s capabilities in viral vector manufacturing, advancing support for cell and gene therapies.
  • March 2023 : Thermo Fisher Scientific set up a cGMP facility at the University of California, San Francisco's Mission Bay campus, to accelerate cell therapies for cancers and other hard-to-treat diseases. The facility focuses on advancing CAR-T and CRISPR technologies, offering comprehensive drug development and manufacturing services.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
24
RESEARCH METHODOLOGY
29
EXECUTIVE SUMMARY
42
PREMIUM INSIGHTS
45
MARKET OVERVIEW
This Section Covers the Market Dynamics, and Upcoming Trends Shaping the CRISPR Market.
47
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing demand for CRISPR-based gene therapies
    - Advancements in CRISPR technology
    - Growing government and private investments and funding for CRISPR technology
    RESTRAINTS
    - Technical challenges associated with CRISPR technology
    OPPORTUNITIES
    - Development of new vaccines and treatments for genetic diseases
    - Expanding industrial and agricultural applications of CRISPR
    CHALLENGES
    - Regulatory hurdles for CRISPR advancements
    TECHNOLOGY ANALYSIS
    - Key technologies
    - Complementary technologies
    - Adjacent technologies
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
  • 5.9 PRICING ANALYSIS
    AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
    AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022–2024
    INDICATIVE PRICE TREND FOR CRISPR SERVICES
    AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024
  • 5.10 PATENT ANALYSIS
  • 5.11 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    CRISPR MARKET: BUYING CRITERIA
  • 5.13 INVESTMENT & FUNDING SCENARIO
  • 5.14 IMPACT OF AI ON CRISPR MARKET
  • 5.15 TRADE ANALYSIS
    IMPORT DATA FOR KITS & REAGENTS, 2019–2023
    EXPORT DATA FOR KITS & REAGENTS, 2019–2023
    TRUMP IMPACT OVERVIEW: CRISPR MARKET
    - Introduction
    - Key tariff rates
    - Price impact analysis
    - Key Impact on various regions
    - End-use industry impact
CRISPR MARKET, BY OFFERING
Market Assessment for CRISPR Market, By Offering : Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million))
90
  • 6.1 INTRODUCTION
  • 6.2 PRODUCTS
    ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 6.3 SERVICES
    GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET
CRISPR PRODUCTS MARKET, BY TYPE
Market Assessment for CRISPR Market, By Type : Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
96
  • 7.1 INTRODUCTION
  • 7.2 CRISPR KITS & ENZYMES
    CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
  • 7.3 CRISPR LIBRARIES
    INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
  • 7.4 OTHER PRODUCTS
CRISPR PRODUCTS MARKET, BY END USER
End User-Specific Market Assessment for CRISPR Products Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
104
  • 8.1 INTRODUCTION
  • 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
  • 8.3 ACADEMIC & RESEARCH INSTITUTES
    INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
  • 8.4 OTHER END USERS
CRISPR MARKET, BY SERVICE
Market Assessment for CRISPR Market, By Service Type : Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
112
  • 9.1 INTRODUCTION
    GRNA SYNTHESIS & CELL LINE DEVELOPMENT
    - Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
    SCREENING & VALIDATION
    - Rapid advancements in CRISPR technology to drive growth
  • 9.2 OTHER SERVICES
CRISPR SERVICES MARKET, BY END USER
End User-Specific Market Assessment for CRISPR Services Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
120
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 10.3 ACADEMIC & RESEARCH INSTITUTES
    INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
  • 10.4 OTHER END USERS
CRISPR MARKET, BY APPLICATION
Market Assessment for CRISPR Market, By Application : Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
128
  • 11.1 INTRODUCTION
  • 11.2 DRUG DISCOVERY & DEVELOPMENT
    ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • 11.3 AGRICULTURE
    GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
  • 11.4 OTHER APPLICATIONS
CRISPR MARKET, BY REGION
Region and Country-level Assessment for CRISPR Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
136
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK OF NORTH AMERICA
    US
    - Increasing demand for CRISPR products and services across various industries to drive growth
    CANADA
    - Increasing demand for gene-editing technologies to boost growth
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK OF EUROPE
    GERMANY
    - Rapidly increasing biotechnology sector to support growth
    UK
    - Significant government investments in genomics research to propel growth
    FRANCE
    - Increasing demand for targeted therapies and personalized medicine to propel growth
    ITALY
    - Increasing demand for innovative therapeutic solutions to drive growth
    SPAIN
    - Increasing demand for precision medicine to drive growth
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing investments in R&D to drive growth
    JAPAN
    - Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
    INDIA
    - Increasing prevalence of genetic disorders to support growth
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Growing adoption of genome technologies to propel growth
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
This Section Covers Strategic Analysis of Key Players, Market Shares (%), Revenue Analysis (USD Million), Competitive Mapping and Benchmarking for Key Players and SMEs/Start-ups
190
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
  • 13.3 REVENUE ANALYSIS, 2020−2024
  • 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Product footprint
    - Service footprint
    - Application footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 13.7 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
  • 13.8 COMPANY VALUATION & FINANCIAL METRICS
  • 13.9 BRAND/PRODUCT COMPARISON
COMPANY PROFILES
In-depth Profiling of Key Players and SMEs/Start-ups Operating in the CRISPR Market: Business Overview, Offerings, Recent Developments
208
  • 14.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    MERCK KGAA
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    GENSCRIPT
    - Business overview
    - Products/Services offered
    - Recent developments
    REVVITY
    - Business overview
    - Products/Services offered
    - Recent developments
    LONZA
    - Business overview
    - Products/Services offered
    - Recent developments
    DANAHER CORPORATION
    - Business overview
    - Products/Services offered
    - Recent developments
    TAKARA BIO INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    CREATIVE BIOGENE
    - Business overview
    - Products/Services offered
    - Recent developments
    FUJIAN SUNYBIOTECH CO., LTD.
    - Business overview
    - Products/Services offered
    EDITCO
    - Business overview
    - Products/Services offered
    - Recent financials
    CARIBOU BIOSCIENCES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    HERA BIOLABS
    - Business overview
    - Products/Services offered
    ORIGENE TECHNOLOGIES, INC.
    - Business overview
    - Products/Services offered
    CELLECTA, INC.
    - Business overview
    - Products/Services offered
  • 14.2 OTHER PLAYERS
    MAMMOTH BIOSCIENCES, INC.
    APPLIED STEMCELL
    NEW ENGLAND BIOLABS
    TOOLGEN, INC.
    GENECOPOEIA, INC.
    TWIST BIOSCIENCE
    SYNTHEGO
    EGENESIS
    INSCRIPTA, INC.
    PRECISION BIOSCIENCES
APPENDIX
259
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 CRISPR MARKET: RISK ANALYSIS
  • TABLE 3 CRISPR MARKET: IMPACT ANALYSIS
  • TABLE 4 CRISPR MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 5 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022–2024
  • TABLE 12 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024 (USD)
  • TABLE 13 CRISPR MARKET: INNOVATIONS AND PATENT REGISTRATIONS
  • TABLE 14 CRISPR MARKET: KEY CONFERENCES & EVENTS, 2025–2026
  • TABLE 15 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 16 IMPORT DATA FOR KITS & REAGENTS, BY REGION, 2019–2023 (USD)
  • TABLE 17 EXPORT DATA FOR KITS & REAGENTS, BY REGION, 2019–2023 (USD)
  • TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 19 KEY TARIFFS ON PHARMACEUTICAL PRODUCTS
  • TABLE 20 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
  • TABLE 21 CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 22 CRISPR PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 23 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 24 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 26 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 CRISPR SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 28 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 CRISPR PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 33 CRISPR KITS & ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 EUROPE: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 CRISPR LIBRARIES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 39 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 44 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 48 CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 49 CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 50 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 EUROPE: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 53 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 55 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 56 EUROPE: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 EUROPE: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 65 CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 67 EUROPE: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 69 LATIN AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 70 CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 71 NORTH AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 72 EUROPE: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 74 LATIN AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 75 OTHER CRISPR SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 76 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 79 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 81 CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 EUROPE: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 LATIN AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 86 CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 87 NORTH AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 88 EUROPE: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 ASIA PACIFIC: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 90 LATIN AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 EUROPE: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 LATIN AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 96 CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 97 CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 99 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 101 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 103 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 104 EUROPE: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 107 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 CRISPR MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 113 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 114 NORTH AMERICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 117 NORTH AMERICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 119 NORTH AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 120 US: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 121 US: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 122 US: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 123 US: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 124 US: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 125 US: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 126 CANADA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 127 CANADA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 128 CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 129 CANADA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 130 CANADA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 131 CANADA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 132 EUROPE: KEY MACROINDICATORS
  • TABLE 133 EUROPE: CRISPR MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 134 EUROPE: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 135 EUROPE: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 136 EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 137 EUROPE: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 138 EUROPE: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 139 EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 140 GERMANY: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 141 GERMANY: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 142 GERMANY: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 143 GERMANY: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 144 GERMANY: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 145 GERMANY: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 146 UK: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 147 UK: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 148 UK: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 149 UK: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 150 UK: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 151 UK: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 152 FRANCE: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 153 FRANCE: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 154 FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 155 FRANCE: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 156 FRANCE: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 157 FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 158 ITALY: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 159 ITALY: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 160 ITALY: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 161 ITALY: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 162 ITALY: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 163 ITALY: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 164 SPAIN: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 165 SPAIN: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 166 SPAIN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 167 SPAIN: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 168 SPAIN: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 169 SPAIN: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 170 REST OF EUROPE: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 171 REST OF EUROPE: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 172 REST OF EUROPE: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 173 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 174 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 175 REST OF EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: KEY MACRO INDICATORS
  • TABLE 177 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 184 CHINA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 185 CHINA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 186 CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 187 CHINA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 188 CHINA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 189 CHINA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 190 JAPAN: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 191 JAPAN: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 192 JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 193 JAPAN: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 194 JAPAN: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 195 JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 196 INDIA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 197 INDIA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 198 INDIA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 199 INDIA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 200 INDIA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 201 INDIA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 202 REST OF ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 203 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 204 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 205 REST OF ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 206 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 207 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 208 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 209 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 210 LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 211 LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 212 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 213 LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 215 LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 216 BRAZIL: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 217 BRAZIL: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 218 BRAZIL: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 219 BRAZIL: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 220 BRAZIL: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 221 BRAZIL: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 222 REST OF LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 223 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 224 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 225 REST OF LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 226 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 227 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 228 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 229 MIDDLE EAST & AFRICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 230 MIDDLE EAST & AFRICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
  • TABLE 231 MIDDLE EAST & AFRICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 232 MIDDLE EAST & AFRICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 233 MIDDLE EAST & AFRICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 234 MIDDLE EAST & AFRICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 235 STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, 2021−2025
  • TABLE 236 CRISPR MARKET: DEGREE OF COMPETITION
  • TABLE 237 CRISPR MARKET: REGION FOOTPRINT
  • TABLE 238 CRISPR MARKET: PRODUCT FOOTPRINT
  • TABLE 239 CRISPR MARKET: SERVICE FOOTPRINT
  • TABLE 240 CRISPR MARKET: APPLICATION FOOTPRINT
  • TABLE 241 CRISPR MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 242 CRISPR MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
  • TABLE 243 CRISPR MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025
  • TABLE 244 CRISPR MARKET: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 245 CRISPR MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 246 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 247 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 248 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 249 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 250 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 251 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 252 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 253 MERCK KGAA: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 254 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 255 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 256 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 257 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 258 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 259 GENSCRIPT: PRODUCTS/SERVICES OFFERED
  • TABLE 260 GENSCRIPT: PRODUCT/SERVICE APPROVALS/LAUNCHES, JANUARY 2021–MARCH 2025
  • TABLE 261 GENSCRIPT: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 262 GENSCRIPT: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 263 REVVITY: COMPANY OVERVIEW
  • TABLE 264 REVVITY: PRODUCTS/SERVICES OFFERED
  • TABLE 265 REVVITY: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 266 LONZA: COMPANY OVERVIEW
  • TABLE 267 LONZA: PRODUCTS/SERVICES OFFERED
  • TABLE 268 LONZA: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 269 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 270 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 271 DANAHER CORPORATION: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 272 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 273 TAKARA BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 274 TAKARA BIO INC.: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 275 CREATIVE BIOGENE: COMPANY OVERVIEW
  • TABLE 276 CREATIVE BIOGENE: PRODUCTS/SERVICES OFFERED
  • TABLE 277 CREATIVE BIOGENE: PRODUCT/SERVICE APPROVALS/LAUNCHES, JANUARY 2021–MARCH 2025
  • TABLE 278 FUJIAN SUNYBIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 279 FUJIAN SUNYBIOTECH CO., LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 280 EDITCO: COMPANY OVERVIEW
  • TABLE 281 EDITCO: PRODUCTS/SERVICES OFFERED
  • TABLE 282 EDITCO: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 283 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 284 CARIBOU BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 285 CARIBOU BIOSCIENCES, INC.: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 286 HERA BIOLABS: COMPANY OVERVIEW
  • TABLE 287 HERA BIOLABS: PRODUCTS/SERVICES OFFERED
  • TABLE 288 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 289 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 290 CELLECTA, INC.: COMPANY OVERVIEW
  • TABLE 291 CELLECTA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 292 MAMMOTH BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 293 APPLIED STEMCELL: COMPANY OVERVIEW
  • TABLE 294 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 295 TOOLGEN, INC.: COMPANY OVERVIEW
  • TABLE 296 GENECOPOEIA, INC.: COMPANY OVERVIEW
  • TABLE 297 TWIST BIOSCIENCE: COMPANY OVERVIEW
  • TABLE 298 SYNTHEGO: COMPANY OVERVIEW
  • TABLE 299 EGENESIS: COMPANY OVERVIEW
  • TABLE 300 INSCRIPTA, INC.: COMPANY OVERVIEW
  • TABLE 301 PRECISION BIOSCIENCES: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 CRISPR MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 CRISPR MARKET: RESEARCH DESIGN
  • FIGURE 3 CRISPR MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 5 CRISPR MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 CRISPR MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 CRISPR MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 CRISPR MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 CRISPR MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 14 RISING FOCUS ON CRISPR THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
  • FIGURE 15 DRUG DISCOVERY & DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 17 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18 TOP 10 LEADING CRISPR STARTUPS BASED ON INVESTMENTS RAISED IN 2024
  • FIGURE 19 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 20 CRISPR MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 21 CRISPR MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 22 CRISPR MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 23 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 24 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
  • FIGURE 25 AVERAGE SELLING PRICE OF KITS & REAGENTS, BY REGION, 2024 (USD)
  • FIGURE 26 PATENT APPLICATIONS FOR CRISPR (JANUARY 2014–DECEMBER 2024)
  • FIGURE 27 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 28 KEY BUYING CRITERIA OF END USERS FOR CRISPR PRODUCTS
  • FIGURE 29 KEY SELECTION CRITERIA OF END USERS FOR CRISPR SERVICES
  • FIGURE 30 CRISPR MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 31 IMPACT OF AI/GEN AI ON CRISPR MARKET
  • FIGURE 32 NORTH AMERICA: CRISPR MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: CRISPR MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2020−2024
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2024
  • FIGURE 36 CRISPR MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 37 CRISPR MARKET: COMPANY FOOTPRINT
  • FIGURE 38 CRISPR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 40 EV/EBITDA OF KEY PLAYERS, 2024
  • FIGURE 41 CRISPR MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 45 GENSCRIPT: COMPANY SNAPSHOT (2023)
  • FIGURE 46 REVVITY: COMPANY SNAPSHOT (2024)
  • FIGURE 47 LONZA: COMPANY SNAPSHOT (2024)
  • FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 49 TAKARA BIO INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)

Methodology

The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.

Secondary Research

Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.

Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.

The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.

Primary Research

Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.

The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

CRISPR Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:

CRISPR Market : Top-Down and Bottom-Up Approach

CRISPR Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.

The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.

Key Stakeholders

  • Genome editing/genome engineering product manufacturers
  • CRISPR editing/genome engineering product manufacturers
  • Suppliers and distributors of genomic instruments/systems and consumables
  • Contract manufacturing organizations
  • Pharmaceutical and biotechnology companies
  • Diagnostic centers and medical colleges
  • Contract research organizations
  • Government associations and research institutes
  • Regulatory authorities
  • Business research firms

Report Objectives

  • To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

Geographical Analysis

  • A further breakdown of the Rest of Asia Pacific CRISPR market into countries
  • A further breakdown of the Rest of Europe CRISPR market into countries
  • A further breakdown of the Rest of Latin America CRISPR market into countries

 

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the CRISPR Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in CRISPR Market

DMCA.com Protection Status